ZP
ZNTL icon

Zimmer Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Zimmer Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-55,000
Closed -$2.64M – 161
2020
Q2 		$2.64M Buy
+55,000
New +$2.11M 0.04% 90

Other funds holding ZNTL

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Zimmer Partners's ZNTL Position: Q3 2020 in Review

Zimmer Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2020, closing a stake of 55,000 shares — an estimated $2.64M sold.

Zimmer Partners first reported a position in ZNTL in Q2 2020 and held it in 1 quarter. The position peaked at $2.64M in Q2 2020. 66 funds tracked by Wall St. Rank hold ZNTL as of Q3 2020.

  • Zimmer Partners reported no remaining Zentalis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Zimmer Partners sold 55,000 Zentalis Pharmaceuticals shares in Q3 2020, an estimated $2.64M.
  • Zimmer Partners first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Zimmer Partners's Zentalis Pharmaceuticals position peaked at $2.64M in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2020.

Based on Zimmer Partners's 13F filing for Q3 2020, filed 16 Nov 2020.